Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) Shares Sold by Webster Bank N. A.

Webster Bank N. A. lowered its stake in Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) by 8.5% in the second quarter, HoldingsChannel reports. The institutional investor owned 1,670 shares of the company’s stock after selling 155 shares during the period. Webster Bank N. A.’s holdings in Invesco Biotechnology & Genome ETF were worth $108,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in PBE. Covestor Ltd boosted its position in Invesco Biotechnology & Genome ETF by 24.2% in the first quarter. Covestor Ltd now owns 955 shares of the company’s stock valued at $62,000 after buying an additional 186 shares during the last quarter. Stratos Wealth Partners LTD. purchased a new stake in shares of Invesco Biotechnology & Genome ETF in the 4th quarter valued at $208,000. B. Riley Wealth Advisors Inc. acquired a new stake in shares of Invesco Biotechnology & Genome ETF in the first quarter worth $232,000. Cetera Advisors LLC purchased a new position in shares of Invesco Biotechnology & Genome ETF during the first quarter worth $328,000. Finally, Banque Cantonale Vaudoise lifted its position in Invesco Biotechnology & Genome ETF by 39.0% during the first quarter. Banque Cantonale Vaudoise now owns 5,184 shares of the company’s stock valued at $335,000 after purchasing an additional 1,454 shares during the period.

Invesco Biotechnology & Genome ETF Trading Down 0.1 %

PBE traded down $0.06 during midday trading on Friday, hitting $68.05. 5,622 shares of the company were exchanged, compared to its average volume of 12,181. The company’s 50 day simple moving average is $66.47 and its 200 day simple moving average is $64.81. The firm has a market capitalization of $274.91 million, a price-to-earnings ratio of 17.12 and a beta of 0.88. Invesco Biotechnology & Genome ETF has a 1-year low of $52.47 and a 1-year high of $71.19.

Invesco Biotechnology & Genome ETF Profile

PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies.